Allison DeAngelis, who covers biotech startups and venture capital, is also the author of STAT’s annual report “Ranking Biotech’s Top Venture Capital Firms.” Biotech investors have been ...

Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise. Bright Minds shares DRUG ...

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...

There’s a myth that making money in biotechnology stocks requires an advanced degree. But Robert Duggan, an avid surfer who ...

The cyclical, high-risk, high-reward nature of the biotech industry is on full display in 2024. This industry is centered on using living organisms and bioprocesses for innovative drug development ...

Apr. 23, 2024 — Researchers describe the steps they took to manipulate DNA and proteins -- essential building blocks of life -- to create cells that look and act like cells from the body. This ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or even a handful of world-changing drugs to address ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

The United States's dominance in biotech innovation is crucial to our national interests and global security. In recent years, China has quickly become a powerhouse, bolstered by its biotech ...

Fidelity Select Biotechnology Portfolio earns an Above Average Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance ...